Table 3 Treatment exposure
Reasons for discontinuing XELOXIRI | n = 61 (%) |
|---|---|
Surgery | 26 (42.62%) |
Maintenance treatment | 9 (14.75%) |
AEs | 4 (6.56%) |
Disease progression | 12 (19.67%) |
Loss to follow-up | 5 (8.20%) |
Radiotherapy | 3 (4.92%) |
Ablation | 1 (1.64%) |
Drug discontinuation | n (%) |
Any drug discontinuation | 19 (31.15%) |
Oxaliplatin | 5 (8.20%) |
Irinotecan | 10 (16.39%) |
Capecitabin | 1 (1.64%) |
Oxaliplatin and irinotecan | 2 (3.28%) |
Irinotecan and capecitabin | 1 (1.64%) |
Dose intensity | mg/m2/week |
Oxaliplatin | |
 mean dose intensity | 36.95 |
 median dose intensity | 37.31 |
Irinotecan | |
 mean dose intensity | 71.41 |
 median dose intensity | 71.41 |
Capecitabin | |
 mean dose intensity | 5599.75 |
 median dose intensity | 5599.75 |